214. Comparison of Clinical and Laboratory Findings of Human Monocytic Ehrlichiosis (HME) and Human Granulocytic Anaplasmosis (HGA) in Long Island, New York.

Nancy Azab, MB BCH; Kalie Smith, BS; Eric Spitzer, MD/PhD;
Fredric I. Weinbaum, MD7 and Luz Marcos, MD, MPH7; Stonybrook University Hospital, Stonybrook, New York; 7Stonybrook Southampton Hospital, Southampton, New York; 7Stony Brook University, Stony Brook, New York

Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM

Background. Suffolk County reports to the Department of Health the highest absolute number of cases of tick-borne diseases (TBD) for NY State. While Lyme disease and Babesiosis are the most common TBD in this county with more than 600 and 100 cases reported every year, respectively; two other TBD, HME (due to Ehrlichia chaffeensis) and HGA (due to Anaplasma phagocytophila) are also commonly reported in this county (63 and 37 every year, respectively). There is limited data directly comparing both diseases on acute presentation; the aim of this study was to compare the clinical features, laboratory findings and complications of HME and HGA in the epicenter of TBD in NY State.

Methods. A retrospective study was designed to collect cases with the diagnosis of HME and HGA by using ICD9 or ICD10 codes from 2013 to 2018 at Stony Brook Medicine. Inclusion criteria were patients 18 years or older who had a positive PCR in blood for E. chaffeensis or A. phagocytophila. Demographics, clinical features, laboratory results, and complications were extracted from patient charts. We used the chi-squared test to compare proportions of symptoms and a two-tailed unpaired student t-test to compare laboratory values.

Results. A total of 40 cases of HME (mean age 67 ± 13) and 27 with HGA (mean age 63 ± 12) met inclusion criteria. Only approximately 50% of cases had a documented history of tick exposure. Clinical presentations were similar in terms of frequency of fever, headache, arthralgia, and myalgia. In contrast, hypotension, confusion, and rash were more common in HME only although the latter was significantly more common. HME patients had significantly greater degrees of leukopenia and thrombocytopenia and elevated AST levels. The majority of patients with HME and HGA were hospitalized >1 day for management of their acute illness (HME, 30/40 and HGA 17/27). Several patients with HME had gastrointestinal (GI) complications including 3 with acute acalculous cholecystitis, 3 with duodenitis, and 1 with acute colitis; 1 patient with HGA had perforated diverticulitis.

Conclusion. Patients with acute HME tend to be more ill than those with acute HGA; however, a substantial proportion of both groups require hospitalization. GI complications were more commonly seen in HME (12.5%) than HGA (3.7%) which deserves further investigation.

Disclosures. All authors: No reported disclosures.

215. Invasive Group A Streptococcus (GAS) Associated Hospitalizations and Risk Factors for In-Hospital Mortality Among Adults in California, 2000–2016

Ellora Karmarkar, MD, MSC; Seema Jain, MD; Gail L. Sondermeyer Cooksey, MPH2; Jennifer Myers, MPH2 and Amanda Kamali, MD3; 1Centers for Disease Control and Prevention, Richmond, California; 2California Department of Public Health, Richmond, California

Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM

Background. Invasive group A Streptococcus (GAS) causes severe illness and death but is not vaccine preventable or nationally notifiable. We describe the
epidemiology of adult patients hospitalized with iGAS in California and risk factors for in-hospital death.

Methods. Using 2000–2016 California hospital discharge data, we extracted records for adults (≥18 years) with ≥1 group A Streptococcus (GAS)-associated International Classification of Diseases, Ninth or Tenth Revision discharge diagnosis code (e.g., unspecified GAS: GAS-specific pharyngitis, pneumonia, and sepsis) or known GAS-associated syndromes (e.g., acute rheumatic fever, erysipelas, scarlet fever). To identify patients hospitalized with iGAS, we selected extracted records that also had codes consistent with invasive disease (e.g., sepsis, pneumonia, intubation, or central line placement). We calculated iGAS-associated hospitalization incidence rates per 100,000 population and described patient demographics and comorbidities. We calculated the odds of in-hospital death using multivariable logistic regression (P < 0.05).

Results. During 2000–2016 in California, 37,532 adults were hospitalized with iGAS; 1,045 (3%) died in-hospital. Mean annual hospitalization incidence was 9.4/100,000 population, and was highest (16.3/100,000) in 2016 (Figure 1). Most patients were male (56%), aged 40–65 (45%) or ≥65 (28%) years, and white (60%); 18% were immunocompromised. The percent of patients who died in-hospital increased with age and was highest among those with comorbidities such as malnutrition, cardiorenal or central diabetes (CVD), and chronic kidney disease (CKD) (Figure 2). In a multi-variable model including age as a continuous variable, sex, and race/ethnicity, the odds of in-hospital death was significantly increased for patients with diagnosis codes for malnutrition, liver disease, CVD, immunosuppression, and CKD (Figure 2); within the race/ethnicity variable Asian/Pacific Islander patients had a higher odds of death compared with white patients.

Conclusion. Hospitalization and subsequent in-hospital death due to iGAS is substantial in California. Adults with iGAS who have specific comorbidities are at greater risk for death when hospitalized with iGAS.

Figure 1: Annual number of patients hospitalized with invasive group A Streptococcus and hospitalization rate (per 100,000 population), California, 2000–2016.

Figure 2: Percent of patients hospitalized with invasive group A Streptococcus infection who died in-hospital, and the adjusted odds of in-hospital death calculated using multivariable logistic regression, California, 2000–2016.

Disclosures. All authors: No reported disclosures.

216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bacterial Infections (GN-BSI)
Thomas Lodise, PharmD1; Hermandh Kanakamedala, BS2; Wei-Chun Hsu, MS3 and Bin Cai, MD, PhD1; 1Albany College of Pharmacy and Health Sciences, Albany, New York; 2Genesis Research Inc., Hoboken, New Jersey; 3Shionogi Inc., Parsippany, New Jersey

Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM

Background. The deleterious outcomes associated with delay receipt of appropriate therapy are well documented. However, scant data exists on the consequences of each day delay of appropriate therapy and subsequent outcomes among adult hospitalized patients with GN-BSIs.

Methods. Study design: a retrospective cohort analysis. Study population: consecutive adult hospitalized patients with a GN-BSI (11 most prevalent pathogens) in 1 of 181 institutions contributing microbiology data to the Premier Healthcare Database (October 2010–September 2015). Exclusion criteria: age <18 years; diagnosis of pregnancy or cystic fibrosis, died or discharged within 2 days of index GN-BSI culture, lack of sufficient antibiotic susceptibility or treatment data to determine appropriateness. Day of initiating appropriate therapy was defined as the first day when the patient received an antibiotic with in vitro activity against the GN-BSI index culture. Results were summarized by Kaplan–Meier estimates, and Cox Proportional-Hazards (CPH) analysis modeling discharge to home were conducted. Time to initiate appropriate therapy (0–1 days, 1–2 days, 2–3 days, ≥5 days) was included in the CPH model as an ordinal variable.

Results. A total of 40,549 patients met selection criteria. Mean age was 67.5 (16.1) years and 54% were female. E. coli and K. pneumoniae were the most common GN-BSI (58.0% and 18.3%, respectively). Approximately 30% of patients were in the ICU at index GN-BSI and in-hospital mortality was 6.8%. The mean (SD) time to receive appropriate therapy post index GN-BSI culture was 0.6 (2.7) days, and 69.7%, 22.5%, 5.7% and 2.1% received appropriate therapy in 0–1, 1–2, 2–3, and ≥5 days of index GN-BSI, respectively. The mean/median LOS post index GN-BSI by 0–1, 1–2, 2–3, and ≥5 days delays in appropriate treatment were 8.3/6, 9.8/7, 11.5/8, and 19.2/11 days respectively. Kaplan–Meier plots are shown in Figure 1. In the CPH model, each interval delay in appropriate therapy was associated with a 21% decrease in the likelihood of being discharged home for patients with GB-BSIs.

Conclusion. Hospital length of stay was found to increase when appropriate therapy was delayed. These findings highlight the critical need for early appropriate therapy among patients with GN-BSIs.

Disclosures. All authors: No reported disclosures.

217. Combination Salvage Therapy with Cefazolin Plus Ertapenem for Refractory Methicillin-Susceptible Staphylococcus aureus Bacteremia
Erlinda Rose Ulooa, MD,MSc; Kavindra V. Singh, PhD1; Matthew Geriak, PharmD2; Fadi Haddad, MD3; Barbara E. Murray, MD1; Victor Nizet, MD4 and George Saksoules, MD5; 1The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; 2Center for Antimicrobial Resistance and Microbial Genomics, UTHHealth, Houston, Texas, Houston, Texas; 3Sharp Hospital, San Diego, California; 4University of California San Diego, La Jolla, California; 5University of California San Diego, San Diego, California

Session: 37. Bacteremia, CLABSI, and Endovascular Infections
Thursday, October 3, 2019: 12:15 PM

Background. Suboptimal therapy against methicillin-sensitive Staphylococcus aureus (MSSA) may have catastrophic consequences in severe infections such as endocarditis or epidural abscess. High MSSA inocula have been associated with clinical failure in patients receiving cefazolin (CZ), particularly when used at low doses, associated with a CZ inoculum effect. We previously described that adding ertapenem (ETP) to CZ led to synergism against MSSA and sensitized the pathogen to host innate immune factors. Here we expand our experience with CZ plus ETP as salvage therapy for 11 cases of refractory MSSA bacteremia (lacking source control problems) and explore CZ+ETP combination in vitro and in vivo.

Methods. Six available MSSA strains from patients treated with CZ+ETP for refractory bacteremia were tested in Mueller–Hilton Broth or RPMI media at standard (105 CFU/mL) or high (106 CFU/mL) inocula by MIC, checkerboard, and time-kill assays using ETP, CZ or nafcillin (NAF) alone vs. ETP+NAF or ETP+CZ. Disk diffusion synergy assays between CZ and ETP were also performed. CZ, ETP and CZ+ETP were tested in a rat endocarditis model using well described MSSA, TX0117 and TX0117c.

Disclosures. All authors: No reported disclosures.